When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company has to approach the DCGI for approval to commence the trials
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The boy becomes India’s youngest recipient to undergo bilateral lung transplantation.
The company to receive upfront and milestone payments, in addition to royalties
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Subscribe To Our Newsletter & Stay Updated
